Research & Education

Malignant Pleural Mesothelioma - Multidisciplinary Treatment Update

Wednesday July 27, 2016 9:00PM EDT - Recording Available
 Lauren Averett Byers  

Joseph S. Friedberg, MD, FACS
Charles Reid Edwards Professor of Surgery
Thoracic Surgeon-in-Chief
University of Maryland Medical System
Baltimore, Maryland

Anne S. Tsao, MD
Associate Professor
Director, Mesothelioma Program
Director, Thoracic Chemo-Radiation Program
University of Texas M.D.
Anderson Cancer Center
Department of Thoracic
Head & Neck Medical Oncology

Name of Reviewer(s): 


Fred Hirsch, MD, PhD –Advisory/Speakers boards: Genentech/Roche, Lilly, AstraZeneca, BMS, Merck, Ventana, Novartis, HTG

Name of Planner(s): 


Pia Hirsch-Nothing to Disclose      Carlos Ferreira-Nothing to Disclose


Name of Activity: 


Malignant Pleural Mesothelioma - Multidisciplinary Treatment Update

Date of Activity:




COI Resolution: Ensure a balanced discussion of alternative. Do not use trade names. Do not refer to company names or logos. Do not recommend therapies.

“All planning committee members’ and/or faculty’s identified conflicts of interest pertaining to this activity were resolved prior to the activity.”

Speaker: Joseph S. Friedberg, MD, FACS- Has nothing to disclose

Speaker: Anne S. Tsao, MD- Speaker &Advisory board for  Genentech/Roche, Boehringer Ingelheim, Ariad, Novartis, AstraZeneca

Type of Activity:

 Live Course

  Internet Live Course (Webinar)XXXX

 Internet Enduring Material

Are there Commercial Supporters for this activity?


If yes, please list: This webinar was supported by a grant from Mesothelioma Foundation

Malignant Pleural Mesothelioma (MPM) remains one of the most intractable malignancies, with current overall survival (OS) of about 12 months in unresectable advanced stages.  Multimodality therapy in resectable patients yields median OS of 17-25 months.  Recently, the field has made several advances due to novel discoveries and initiatives in epidemiology, screening/detection and treatment.  Anti-angiogenic and immunotherapy in the resectable and advanced settings may alter the standard of care treatment alogorithms.  This webinar features two presentations:

The Role of Surgery for Mesothelioma - Joseph Friedberg, MD

  • This presentation will discuss the role of surgery in the treatment of malignant pleural mesothelioma, including the controversial status of this modality.

 Updates on Systemic Therapy of Malignant Mesothelioma - Anne S. Tsao, MD

  • This presentation will discuss the latest advances in systemic therapy for malignant mesothelioma. 
  • A discussion on anti-angiogenic therapy in the frontline setting and an update on the results from the COMMAND and DETERMINE trials will be given. 
  • Ongoing immunotherapy and mesothelin targeted studies will also be reviewed.

After participating in this program attendees will:

  • Assess the current status of surgery for mesothelioma
  • Identify patients most likely to benefit from a surgical approach
  • Demonstrate the limitations and advantages of the different surgical approaches
  • Illustrate current standard mesothelioma therapies
  • Summarize the evolving roles of anti-angiogenic therapy in advanced disease and the current status of new immunotherapies under investigation in mesothelioma

This sixty minute program will be an interactive event and there will be ample opportunity for attendees to e-mail their questions and comments to the faculty for fruitful exchange



IASLC Financial/Commercial Relationships and Conflicts of Interest Policy

IASLC Honoraria Policy

IASLC Commercial Support Agreement (LOA)

This live webinar series is designed to meet the educational needs of radiation oncologists, medical oncologists, thoracic surgeons, radiologists, pathologists, and advanced practice nurses, physician's assistants and other healthcare professionals who diagnose and treat patients with lung cancer.

In order to receive CME credit, attendees must fill out a program evaluation.

Use the Time Zone Converter